lupus

photo of the exterior of EMD Serono
Biotech

After setback, Merck KGaA shows data justifying lupus ph. 3 push

Merck evaluated the oral TLR7/8 inhibitor enpatoran in a dual phase 2 WILLOW study that separately assessed the drug in two forms of lupus.
James Waldron May 21, 2025 9:50am
AI drug discovery pill machine learning drug targets data

Charles River and Valo pact nets preclinical lupus asset

Mar 26, 2025 6:30am
bumpy road rough bad path

Merck KGaA fails lupus trial arm, plans further development

Mar 6, 2025 7:25am
race car photo finish speed fast

Cabaletta's CAR-T shows 'robust benefit' in autoimmune patients

Feb 19, 2025 11:10am
Male and female superheroes posing in fluttering cloaks

Conduit taps Charles River to build AZ asset’s autoimmune cred

Feb 13, 2025 12:51pm
crown royalty king queen win

Biogen taps Royalty for $250M to fund phase 3 lupus program

Feb 12, 2025 8:10am